What is the average price of levodopa-carbidopa exports from India?

The average unit price for levodopa-carbidopa exports from India is $1.20 USD per unit, with prices ranging from $0.27 to $18.21 depending on formulation, packaging, and order volume. The total market is valued at $7.5K across 57 shipments.

Which ports handle levodopa-carbidopa exports from India?

The primary ports for levodopa-carbidopa exports from India are Delhi Air (26.3% of shipments), Bombay Air (21.1% of shipments), Delhi Air Cargo (12.3% of shipments), SAHAR AIR CARGO ACC (INBOM4) (7.0% of shipments), DELHI AIR (7.0% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Why is India a leading exporter of levodopa-carbidopa?

India is one of the world's leading exporters of levodopa-carbidopa due to its large base of 21 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports levodopa-carbidopa to 19 countries, demonstrating 10% global market coverage.

What certifications do Indian levodopa-carbidopa exporters need?

Indian levodopa-carbidopa exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

How many buyers import levodopa-carbidopa from India?

There are 19 registered buyers importing levodopa-carbidopa from India, spread across 19 countries. The repeat buyer rate is 63.2%, indicating strong long-term trade relationships and consistent product quality.

What is the market share of the top levodopa-carbidopa supplier from India?

RMPL PHARMA LLP is the leading levodopa-carbidopa exporter from India with a market share of 27.8% and total export value of $2.1K across 4 shipments. The top 5 suppliers together control 57.4% of total export value.

Levodopa-carbidopa

India Pharmaceutical Trade Intelligence

$7.5K21 Suppliers19 CountriesHS 30049099

ExportsIndia → SOMALIA30.3%India → TURKEY15.2%

#1 Supplier: RMPL PHARMA #1 Buyer: K.S. ATLAS

Levodopa-carbidopa Export Data from India (2026) — Suppliers, Buyers & Trade Stats | TransData Nexus | TransData Nexus

How India Exports Levodopa-carbidopa to the World

Q: Who are the top levodopa-carbidopa exporters from India?

The top levodopa-carbidopa exporters from India are: 1. RMPL PHARMA LLP — $2.1K (27.8% market share); 2. RIZLIFE HEALTHCARE — $1.1K (15.2% market share); 3. ANR HEALTH CARE PRIVATE LIMITED — $1.1K (14.5% market share). Together they account for 57.4% of India's total levodopa-carbidopa export value.

Q: What is the total export value of levodopa-carbidopa from India?

The total export value of levodopa-carbidopa from India is $7.5K USD, recorded across 57 shipment transactions from 21 active exporters to 19 destination countries. The average shipment value is $131.

Q: Which countries import levodopa-carbidopa from India?

India exports levodopa-carbidopa to 19 countries worldwide. The top importing countries are: SOMALIA (30.3% share, $2.3K), TURKEY (15.2% share, $1.1K), UNITED ARAB EMIRATES (14.5% share, $1.1K), ETHIOPIA (11.2% share, $836), TANZANIA (6.9% share, $514). These five markets account for 78.0% of total export value.

Between 2022 and 2026, India exported $7.5K worth of levodopa-carbidopa across 57 verified shipments to 19 countries — covering 10% of world markets in the Combination Drugs segment. The largest destination is SOMALIA (30.3%). RMPL PHARMA LLP leads with a 27.8% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Levodopa-carbidopa export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Levodopa-carbidopa export data snapshot — $7.5K · 21 exporters · 19 countriesTransData Nexus · Indian Customs Data

Top Levodopa-carbidopa Exporters from India

21 active exporters · Ranked by export value

View all 21 →

Top Levodopa-carbidopa Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	RMPL PHARMA LLP	$2.1K	4	1	27.8%
2	RIZLIFE HEALTHCARE

Top Countries Importing Levodopa-carbidopa from India

19 destination markets · Ranked by import value

All 19 countries →

Top Countries Importing Levodopa-carbidopa from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	SOMALIA	$2.3K	30.3%
2	TURKEY	$1.1K	15.2%
3	UNITED ARAB EMIRATES	$1.1K	14.5%
4	ETHIOPIA	$836	11.2%
5	TANZANIA	$514	6.9%
6	ZAMBIA	$505	6.8%
7	YEMEN	$287	3.8%
8	SUDAN	$195	2.6%
9	TAJIKISTAN	$110	1.5%
10	CONGO	$109	1.5%

SOMALIA is India's largest levodopa-carbidopa export destination, absorbing 30.3% of total exports worth $2.3K. The top 5 importing countries — SOMALIA, TURKEY, UNITED ARAB EMIRATES, ETHIOPIA, TANZANIA — together account for 78.0% of India's total levodopa-carbidopa export value. The remaining 14 destination countries collectively receive the other 22.0%, indicating a focused distribution strategy targeting key markets.

Regulatory Landscape — Levodopa-carbidopa

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

Levodopa-carbidopa has been a cornerstone in the treatment of Parkinson's disease in the United States. According to the FDA's Orange Book, numerous Abbreviated New Drug Applications (ANDAs) have been approved for this combination, reflecting its established presence in the market. Recent approvals include generic versions by various manufacturers, underscoring the competitive landscape. The regulatory pathway for these generics involves demonstrating bioequivalence to the reference listed drug, ensuring therapeutic equivalence.

Regarding import alerts, as of February 19, 2026, the FDA has issued Import Alert 66-41, which pertains to the detention without physical examination of unapproved new drugs promoted in the U.S. While this alert is not specific to levodopa-carbidopa, it underscores the FDA's vigilance in monitoring drug imports. Given the 21 active Indian exporters of levodopa-carbidopa, adherence to FDA regulations is paramount to ensure market access and compliance.

2EU & UK Regulatory Framework

In the European Union, levodopa-carbidopa combinations have been authorized for the treatment of Parkinson's disease. For instance, the European Medicines Agency (EMA) granted marketing authorization for Stalevo, a combination of levodopa, carbidopa, and entacapone, on October 17, 2003. This product is indicated for adult patients with Parkinson's disease experiencing end-of-dose motor fluctuations not stabilized on levodopa/dopa-decarboxylase inhibitor treatment. Manufacturers exporting to the EU must comply with the EMA's Good Manufacturing Practice (GMP) requirements, ensuring product quality and safety.

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the authorization and regulation of medicinal products. Post-Brexit, the UK has established its own regulatory framework, though it closely aligns with EU standards. Exporters must ensure compliance with MHRA guidelines to access the UK market.

3WHO Essential Medicines & Global Standards

Levodopa-carbidopa is listed in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its critical role in managing Parkinson's disease. The 24th edition of this list, published on September 5, 2025, includes this combination therapy. Inclusion in the WHO Model List signifies the medicine's importance in addressing global health needs. Additionally, levodopa-carbidopa formulations are standardized in various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality and efficacy across different regions.

4India Regulatory Classification

In India, levodopa-carbidopa is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines under the Drug Price Control Order (DPCO). As of the latest notification, the ceiling price for levodopa-carbidopa combinations has been set to ensure affordability and accessibility. Exporters are required to obtain a No Objection Certificate (NOC) from the DGFT for the export of pharmaceutical products, ensuring compliance with national regulations and monitoring of drug exports.

5Patent & Exclusivity Status

The primary patents for levodopa-carbidopa combinations have expired, leading to a robust generic market. This expiration has facilitated increased competition among manufacturers, resulting in more affordable options for patients globally. However, certain formulations or delivery methods may still be under patent protection, necessitating careful consideration by exporters to avoid infringement.

6Recent Industry Developments

In the past 12 months, several developments have impacted the levodopa-carbidopa market:

1. API Price Fluctuations: In June 2025, the NPPA reported a 5% increase in the price of active pharmaceutical ingredients (APIs) for levodopa and carbidopa, attributed to supply chain disruptions.

2. Regulatory Approvals: In September 2025, the EMA approved a new generic formulation of levodopa-carbidopa, expanding treatment options within the EU.

3. Policy Changes: In December 2025, the CDSCO implemented revised guidelines for the export of pharmaceutical products, emphasizing stricter quality control measures to align with international standards.

These developments highlight the dynamic nature of the pharmaceutical industry and the importance of staying informed to navigate regulatory landscapes effectively.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Levodopa-carbidopa

Retail & reference prices across 9 markets vs. India FOB export price of $1.20/unit

Global Price Benchmark for Levodopa-carbidopa across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$0.16	USD	According to the FDA Orange Book, generic versions of Levodopa-Carbidopa are available, contributing to competitive pricing.
United Kingdom	$0.16	GBP	The NHS Drug Tariff lists Levodopa-Carbidopa 100 mg/25 mg tablets, ensuring standardized pricing across the UK.
Germany	$0.17	EUR	The Federal Joint Committee (G-BA) includes Levodopa-Carbidopa in its list of reimbursable medications, influencing market prices.
Australia	$0.18

Supply Chain Risk Assessment — Levodopa-carbidopa

API sourcing, concentration risk, storage requirements, and current alerts

MEDIUM RISK

1API Sourcing & Raw Material Dependency

India's pharmaceutical industry, often referred to as the "pharmacy of the world," heavily relies on China for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). Approximately 70% of India's API and KSM requirements are imported from China, creating a significant dependency. This reliance exposes the supply chain to vulnerabilities, as any disruption in Chinese production or export policies can directly impact the availability of essential drugs.

The COVID-19 pandemic underscored these risks when Chinese factory shutdowns led to immediate shortages and price surges for common medications. For instance, the production of amoxicillin, a widely used antibiotic, depends on KSMs predominantly produced in China. Any disruption in this supply chain can cascade through global pharmaceutical production, leading to shortages.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data indicates that the top five exporters of Levodopa-carbidopa from India account for 57.4% of the total export share, with RMPL PHARMA LLP leading at 27.8%. This concentration suggests a moderate risk, as reliance on a limited number of suppliers can lead to supply disruptions if any of these entities face operational challenges.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at boosting domestic API and KSM production. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and 6-APA, essential for antibiotics. These initiatives aim to reduce import dependence and enhance supply chain resilience.

Access Complete Levodopa-carbidopa Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 57 transactions across 19 markets.

Request Demo View Pricing

Frequently Asked Questions — Levodopa-carbidopa Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top levodopa-carbidopa exporters from India?

The leading levodopa-carbidopa exporters from India are RMPL PHARMA LLP, RIZLIFE HEALTHCARE, ANR HEALTH CARE PRIVATE LIMITED. RMPL PHARMA LLP leads with 27.8% market share ($2.1K). The top 5 suppliers together control 57.4% of total export value.

What is the total export value of levodopa-carbidopa from India?

The total export value of levodopa-carbidopa from India is $7.5K, recorded across 57 shipments from 21 active exporters to 19 countries. The average shipment value is $131.

Which countries import levodopa-carbidopa from India?

India exports levodopa-carbidopa to 19 countries. The top importing countries are SOMALIA (30.3%), TURKEY (15.2%), UNITED ARAB EMIRATES (14.5%), ETHIOPIA (11.2%), TANZANIA (6.9%), which together account for 78.0% of total export value.

What is the HS code for levodopa-carbidopa exports from India?

The primary HS code for levodopa-carbidopa exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Levodopa-carbidopa

Levodopa-carbidopa

How India Exports Levodopa-carbidopa to the World

Top Levodopa-carbidopa Exporters from India

Top Countries Importing Levodopa-carbidopa from India

Quick Facts

Related Combination Drugs

Related Analysis

Need Details?

Regulatory Landscape — Levodopa-carbidopa

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Levodopa-carbidopa

Supply Chain Risk Assessment — Levodopa-carbidopa

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Levodopa-carbidopa Trade Intelligence

Frequently Asked Questions — Levodopa-carbidopa Exports from India

Who are the top levodopa-carbidopa exporters from India?

What is the total export value of levodopa-carbidopa from India?

Which countries import levodopa-carbidopa from India?

What is the HS code for levodopa-carbidopa exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of levodopa-carbidopa exports from India?

Which ports handle levodopa-carbidopa exports from India?

Why is India a leading exporter of levodopa-carbidopa?

What certifications do Indian levodopa-carbidopa exporters need?

How many buyers import levodopa-carbidopa from India?

What is the market share of the top levodopa-carbidopa exporter from India?

Analysis Methodology